Wave Life Shares Plunge 58% on WVE-007 400 mg Dose Shortfall
Wave Life Sciences shares plunged a record 58% after its 400 mg dose of WVE-007 achieved under 1% total fat reduction, 5% visceral fat loss and 0.2% lean mass loss at three months. A post-hoc analysis showed a 7.8% visceral fat decline in patients with higher baseline levels.
1. Trial Results Miss Expectations
At the 400 mg dose, WVE-007 delivered under 1% total fat reduction, 5% visceral fat loss and a 0.2% lean mass decline after three months, falling short of the 240 mg cohort's earlier 4% total fat and 9.2% visceral fat reductions.
2. Record Share Decline
Wave Life shares tumbled 58% at New York open, marking their largest-ever intraday drop and extending a year-to-date slump of 28% through the prior close.
3. Subsequent Reanalysis
A post-hoc examination focusing on patients with higher baseline visceral fat showed an average 7.8% decline, suggesting dose efficacy may vary by starting body composition.
4. Executive Commentary
CEO Paul Bolno emphasized regulatory focus on body composition improvements over scale weight, projecting that WVE-007's lean mass preservation could bolster its approval prospects despite initial data setbacks.